|
1
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schabath MB, Giuliano AR, Thompson ZJ,
Amankwah EK, Gray JE, Fenstermacher DA, Jonathan KA, Beg AA and
Haura EB: TNFRSF10B polymorphisms and haplotypes associated with
increased risk of death in non-small cell lung cancer.
Carcinogenesis. 34:2525–2530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: GLOBOCAN 2008: Cancer Incidence and
Mortality Worldwide. IARC Cancerbase No, 10International Agency for
Research on Cancer. Lyon: 2010, View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bechet D: Magnesium in health &
disease. Magnesium Res. 29:602016.
|
|
6
|
Cardinali DP: The human body circadian:
How the biologic clock influences sleep and emotion. Neuro
Endocrinol Lett. 21:9–15. 2000.PubMed/NCBI
|
|
7
|
Liu B, Xu K, Jiang Y and Li X: Aberrant
expression of Per1, Per2 and Per3 and their prognostic relevance in
non-small cell lung cancer. Int J Clin Exp Pathol. 7:7863–7871.
2014.PubMed/NCBI
|
|
8
|
Chen-Goodspeed M and Lee CC: Tumor
suppression and circadian function. J Biol Rhythms. 22:291–298.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gery S, Komatsu N, Kawamata N, Miller CW,
Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H and Koeffler
HP: Epigenetic silencing of the candidate tumor suppressor gene
Per1 in non-small cell lung cancer. Clin Cancer Res.
13:1399–1404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Couto P, Miranda D, Vieira R, Vilhena A,
De Marco L and Bastos-Rodrigues L: Association between CLOCK,
PER3 and CCRN4L with non-small cell lung cancer in
Brazilian patients. Mol Med Rep. 10:435–440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Retnam L, Chatikavanij P, Kunjara P,
Paramastri YA, Goh YM, Hussein FN, Mutalib AR and Poosala S: Laws,
Regulations, guidelines and standards for animal care and use for
scientific purposes in the countries of Singapore, Thailand,
Indonesia, Malaysia, and India. ILAR J. 57:312–323. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chung S, Son GH and Kim K: Circadian
rhythm of adrenal glucocorticoid: Its regulation and clinical
implications. Biochim Biophys Acta. 1812:581–591. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Savvidis C and Koutsilieris M: Circadian
rhythm disruption in cancer biology. Mol Med. 18:1249–1660. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Winter SL, Bosnoyan-Collins L, Pinnaduwage
D and Andrulis IL: Expression of the circadian clock genes Per1
and Per2 in sporadic and familial breast tumors. Neoplasia.
9:797–800. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS,
Hsu NC and Chang JG: Disturbance of circadian gene expression in
breast cancer. Virchows Archiv. 454:467–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang
Y, Sesterhenn I, Chokkalingam AP, Danforth KN, Shen MC, et al:
Variants in circadian genes and prostate cancer risk: A
population-based study in China. Prostate Cancer Prostatic Dis.
11:342–348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hwang-Verslues WW, Chang PH, Jeng YM, Kuo
WH, Chiang PH, Chang YC, Hsieh TH, Su FY, Lin LC, Abbondante S, et
al: Loss of corepressor PER2 under hypoxia up-regulates
OCT1-mediated EMT gene expression and enhances tumor malignancy.
Proc Natl Acad Sci USA. 110:12331–12336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller BH, McDearmon EL, Panda S, Hayes
KR, Zhang J, Andrews JL, Antoch MP, Walker JR, Esser KA, Hogenesch
JB and Takahashi JS: Circadian and CLOCK-controlled regulation of
the mouse transcriptome and cell proliferation. Proc Natl Acad Sci
USA. 104:3342–3347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chi C, He ZF, Liu Y, Lin XM and Sun CC:
Expression and clinical significance of circadian gene Per2 in
non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:129–131.
2013.(In Chinese). PubMed/NCBI
|
|
21
|
McQueen CM, Schmitt EE, Sarkar TR, Elswood
J, Metz RP, Earnest D, Rijnkels M and Porter WW: PER2 regulation of
mammary gland development. Development. 145:pii: dev157966. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu L and Lee CC: The circadian clock:
Pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi JS, Hong HK, Ko CH and McDearmon
EL: The genetics of mammalian circadian order and disorder:
Implications for physiology and disease. Nat Rev Genet. 9:764–775.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levi F, Okyar A, Dulong S, Innominato PF
and Clairambault J: Circadian timing in cancer treatments. Annu Rev
Pharmacol Toxicol. 50:377–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelleher FC, Rao A and Maguire A:
Circadian molecular clocks and cancer. Cancer Lett. 342:9–18. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu L and Kettner NM: The circadian clock
in cancer development and therapy. Prog Mol Biol Transl Sci.
119:221–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu L, Pelicano H, Liu J, Huang P and Lee
C: The circadian gene Period2 plays an important role in tumor
suppression and DNA damage response in vivo. Cell. 111:41–50. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Younger ST, Kenzelmann-Broz D, Jung H,
Attardi LD and Rinn JL: Integrative genomic analysis reveals
widespread enhancer regulation by p53 in response to DNA damage.
Nucleic Acids Res. 43:4447–4462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garner E and Raj K: Protective mechanisms
of p53-p21-pRb proteins against DNA damage-induced cell death. Cell
Cycle. 7:277–282. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mirzayans R, Andrais B, Scott A and Murray
D: New insights into p53 signaling and cancer cell response to DNA
damage: Implications for cancer therapy. J Biomed Biotechnol.
2012:1703252012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okabe T, Kumagai M, Nakajima Y, Shirotake
S, Kodaira K, Oyama M, Ueno M and Ikeda M: The impact of HIF1α on
the Per2 circadian rhythm in renal cancer cell lines. PLoS
One. 9:e1096932014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miyazaki K, Wakabayashi M, Hara Y and
Ishida N: Tumor growth suppression in vivo by overexpression of the
circadian component, PER2. Genes Cells. 15:351–358. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Clark SJ and Melki J: DNA methylation and
gene silencing in cancer: Which is the guilty party? Oncogene.
21:5380–5387. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gotoh T, Vila-Caballer M, Santos CS, Liu
J, Yang J and Finkielstein CV: The circadian factor Period 2
modulates p53 stability and transcriptional activity in unstressed
cells. Mol Biol Cell. 25:3081–3093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ
and Chang JG: Deregulated expression of the PER1, PER2 and
PER3 genes in breast cancers. Carcinogenesis. 26:1241–1246.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nagel R, Clijsters L and Agami R: The
miRNA-192/194 cluster regulates the Period gene family and
the circadian clock. FEBS J. 276:5447–5455. 2009. View Article : Google Scholar : PubMed/NCBI
|
